SAGE Therapeutics Inc SAGE:NASDAQ

RT Quote | NASDAQ | USD
Last | 06/21/21 EDT
57.44quote price arrow up+0.56 (+0.98%)
Volume
1,130,930
52 week range
39.61 - 98.39

...

Loading . . .
  • Open56.57
  • Day High58.00
  • Day Low55.40
  • Prev Close57.44
  • 52 Week High98.39
  • 52 Week High Date01/15/21
  • 52 Week Low39.61
  • 52 Week Low Date06/22/20

Key Stats

  • Market Cap3.359B
  • Shares Out58.48M
  • 10 Day Average Volume2.12M
  • Dividend-
  • Dividend Yield-
  • Beta2.04
  • YTD % Change-33.6

KEY STATS

  • Open56.57
  • Day High58.00
  • Day Low55.40
  • Prev Close57.44
  • 52 Week High98.39
  • 52 Week High Date01/15/21
  • 52 Week Low39.61
  • 52 Week Low Date06/22/20
  • Market Cap3.359B
  • Shares Out58.48M
  • 10 Day Average Volume2.12M
  • Dividend-
  • Dividend Yield-
  • Beta2.04
  • YTD % Change-33.6

RATIOS/PROFITABILITY

  • EPS (TTM)11.05
  • P/E (TTM)5.20
  • Fwd P/E (NTM)-8.00
  • EBITDA (MRQ)663.648M
  • ROE (MRQ)44.67%
  • Revenue (MRQ)1.113B
  • Gross Margin (MRQ)99.95%
  • Net Margin (MRQ)57.21%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689...
Kevin Starr
Non-Executive Chairman
Barry Greene
President
Kimi Iguchi
Chief Financial Officer
Address
215 1st St
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
MEDP
Medpace Holdings Inc
182.63+5.09+2.87%
EXEL
Exelixis Inc
22.74+0.33+1.47%
EBS
Emergent BioSolutions Inc
61.09+0.54+0.89%
MYGN
Myriad Genetics Inc
29.26+0.65+2.27%
MYGN
Myriad Genetics Inc
29.26+0.65+2.27%